Glaukos CorpNYSE:GKOS
- LAST PRICE126.7500
- TODAY'S CHANGE (%)-0.9700 (-0.7595%)
- Bid / Lots126.5800/ 2
- Ask / Lots126.9200/ 4
- Open / Previous Close128.0000 / 127.7200
- Day Range
- 52 Week Range
- Volume67,521
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GKOS |
|---|---|---|
| 09:32 ET | 1190 | 128 |
| 09:34 ET | 100 | 128.06 |
| 09:36 ET | 12552 | 128.06 |
| 09:41 ET | 400 | 128.095 |
| 09:45 ET | 677 | 127.38 |
| 09:48 ET | 240 | 127.34 |
| 09:52 ET | 100 | 127.15 |
| 09:54 ET | 200 | 126.74 |
| 09:56 ET | 1490 | 127.185 |
| 09:59 ET | 7889 | 126.91 |
| 10:01 ET | 3954 | 127.3075 |
| 10:03 ET | 600 | 127.285 |
| 10:06 ET | 400 | 127.145 |
| 10:08 ET | 5934 | 126.56 |
| 10:10 ET | 1962 | 126.95 |
| 10:12 ET | 169 | 126.95 |
| 10:14 ET | 700 | 126.94 |
| 10:15 ET | 300 | 126.94 |
| 10:17 ET | 1913 | 127.245 |
| 10:19 ET | 365 | 127.29 |
| 10:28 ET | 400 | 127.05 |
| 10:30 ET | 400 | 127.14 |
| 10:32 ET | 400 | 126.93 |
| 10:33 ET | 161 | 126.94 |
| 10:35 ET | 100 | 126.755 |
| 10:39 ET | 1400 | 126.92 |
| 10:42 ET | 300 | 126.94 |
| 10:44 ET | 300 | 126.945 |
| 10:46 ET | 300 | 126.945 |
| 10:48 ET | 385 | 127.14 |
| 10:50 ET | 537 | 127.2 |
| 10:53 ET | 200 | 127.135 |
| 10:55 ET | 601 | 127.01 |
| 10:57 ET | 100 | 126.93 |
| 11:02 ET | 100 | 126.75 |
Sep 3, 2024
DJ Glaukos Is Maintained at Buy by Stifel, from 8:55AM ET on Tuesday Sep 03, 2024 by Dow Jones
8:55AM ET on Tuesday Sep 03, 2024 by Dow Jones
Aug 28, 2024
DJ Glaukos Is Maintained at Buy by BTIG, from 1:12PM ET on Wednesday Aug 28, 2024 by Dow Jones
1:12PM ET on Wednesday Aug 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Glaukos Corp | 7.0B | -39.6x | --- |
Inspire Medical Systems Inc | 6.2B | 1,072.2x | --- |
Penumbra Inc | 7.4B | 553.3x | +65.82% |
Stevanato Group SpA | 6.2B | 39.6x | --- |
Repligen Corp | 8.0B | -3,335.0x | +15.08% |
Lantheus Holdings Inc | 7.8B | 18.3x | +35.30% |
Company Information
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Contact Information
- Headquarters
- 1 GLAUKOS WAYALISO VIEJO, CA, United States 92656
- Phone
- 949-367-9600
- Fax
- 949-367-9984
Executives
- Chairman of the Board, Chief Executive Officer
- Thomas Burns
- President, Chief Operating Officer
- Joseph Gilliam
- Chief Financial Officer, Senior Vice President
- Alex Thurman
- Chief Development Officer
- Tomas Navratil
- Lead Independent Director
- Mark Foley
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.0B |
|---|---|
Revenue (TTM) | $341.7M |
Shares Outstanding | 55.0M |
Glaukos Corp does not pay a dividend. | |
Beta | 1.03 |
EPS | $-3.20 |
Book Value | $9.40 |
P/E Ratio | -39.6x |
Price/Sales (TTM) | 20.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -39.70% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
